Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

3.0K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
3.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

2.3K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.3K
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

88
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Clostridioides difficile</i> Immunity During Pregnancy and Passive Antibody Transfer to Neonates from Cord Blood and Breast Milk.

Toxins·2026
Same author

A case report on the design and implementation of a multinational blended intensive programme in clinical pharmacy practice.

Currents in pharmacy teaching & learning·2026
Same author

The Air Plasmidome: A Discreet Route for Pathogens and the Transmission of Antibiotic Resistance Genes?

Environmental microbiology·2025
Same author

A Mouse Model of Mild <i>Clostridioides difficile</i> Infection for the Characterization of Natural Immune Responses.

Microorganisms·2024
Same author

The state of play of rodent models for the study of <i>Clostridioides difficile</i> infection.

Journal of medical microbiology·2024
Same author

Anti-S-layer monoclonal antibodies impact <i>Clostridioides difficile</i> physiology.

Gut microbes·2024

Related Experiment Video

Updated: May 5, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

9.3K

Immunization using GroEL decreases Clostridium difficile intestinal colonization.

Séverine Péchiné1, Claire Hennequin, Céline Boursier

  • 1Université Paris-Sud, Faculté de Pharmacie, Equipe d'Accueil 4043, Unité Sous Contrat Institut National de la Recherche Agronomique, Châtenay-Malabry, France.

Plos One
|December 5, 2013
PubMed
Summary

Vaccinating hamsters with Clostridium difficile surface proteins partially protected them from death. Antibodies against the GroEL heat shock protein were found to reduce intestinal colonization by C. difficile.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

26.7K

Related Experiment Videos

Last Updated: May 5, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

9.3K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

8.4K
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

26.7K

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Clostridium difficile causes antibiotic-associated diarrhea and colitis.
  • Pathogenesis involves colonization, followed by toxin production (TcdA, TcdB).
  • Preventing initial colonization is a key therapeutic strategy.

Purpose of the Study:

  • To evaluate C. difficile surface proteins as vaccine antigens.
  • To identify protective antigens against C. difficile intestinal colonization.
  • To confirm the role of GroEL antibodies in reducing C. difficile colonization.

Main Methods:

  • Hamster model vaccination with C. difficile surface proteins.
  • Proteomic analysis of hamster sera to identify protective antigens.
  • Mouse model intranasal immunization with recombinant GroEL protein.

Main Results:

  • Vaccination provided partial protection against mortality in hamsters.
  • Proteomic analysis identified GroEL as a potential protective antigen.
  • Intranasal immunization with GroEL reduced C. difficile intestinal colonization in mice.

Conclusions:

  • C. difficile surface proteins, including GroEL, are potential vaccine candidates.
  • GroEL-specific antibodies may play a role in limiting C. difficile colonization.
  • Targeting GroEL could be a novel approach to prevent C. difficile infections.